Inogen, Inc (INGN) EVP Alison Bauerlein Sells 6,667 Shares
Inogen, Inc (NASDAQ:INGN) EVP Alison Bauerlein sold 6,667 shares of the stock in a transaction on Thursday, August 10th. The shares were sold at an average price of $92.64, for a total value of $617,630.88. Following the completion of the sale, the executive vice president now owns 15,000 shares in the company, valued at $1,389,600. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.
Shares of Inogen, Inc (NASDAQ INGN) traded up 0.10% during mid-day trading on Friday, hitting $91.52. The stock had a trading volume of 154,951 shares. Inogen, Inc has a 12-month low of $50.24 and a 12-month high of $98.33. The stock has a market cap of $1.90 billion, a P/E ratio of 79.44 and a beta of 1.01. The company’s 50 day moving average price is $94.61 and its 200 day moving average price is $82.03.
Inogen (NASDAQ:INGN) last issued its quarterly earnings data on Thursday, August 3rd. The medical technology company reported $0.38 EPS for the quarter, topping analysts’ consensus estimates of $0.28 by $0.10. Inogen had a net margin of 10.36% and a return on equity of 12.45%. The firm had revenue of $64.10 million for the quarter, compared to analyst estimates of $59.99 million. During the same quarter in the previous year, the business posted $0.25 EPS. The firm’s revenue was up 17.4% compared to the same quarter last year. Equities research analysts predict that Inogen, Inc will post $1.21 EPS for the current fiscal year.
WARNING: This piece was posted by American Banking News and is the property of of American Banking News. If you are accessing this piece on another website, it was illegally stolen and reposted in violation of United States & international trademark & copyright law. The legal version of this piece can be accessed at https://www.americanbankingnews.com/2017/08/11/inogen-inc-ingn-evp-alison-bauerlein-sells-6667-shares.html.
A number of institutional investors have recently modified their holdings of the company. Ameritas Investment Partners Inc. purchased a new position in shares of Inogen during the first quarter worth approximately $109,000. Schroder Investment Management Group purchased a new position in shares of Inogen during the second quarter worth approximately $132,000. Victory Capital Management Inc. raised its position in shares of Inogen by 36.1% in the first quarter. Victory Capital Management Inc. now owns 1,729 shares of the medical technology company’s stock worth $134,000 after buying an additional 459 shares in the last quarter. State of Alaska Department of Revenue raised its position in shares of Inogen by 4.1% in the first quarter. State of Alaska Department of Revenue now owns 1,790 shares of the medical technology company’s stock worth $138,000 after buying an additional 70 shares in the last quarter. Finally, Sei Investments Co. raised its position in shares of Inogen by 38.1% in the second quarter. Sei Investments Co. now owns 1,606 shares of the medical technology company’s stock worth $153,000 after buying an additional 443 shares in the last quarter.
Several analysts have recently issued reports on the company. BidaskClub upgraded Inogen from a “buy” rating to a “strong-buy” rating in a research note on Tuesday. Zacks Investment Research cut Inogen from a “strong-buy” rating to a “hold” rating in a research note on Tuesday. Stifel Nicolaus increased their price objective on Inogen from $65.00 to $75.00 and gave the company a “hold” rating in a research note on Wednesday, May 10th. Needham & Company LLC increased their price objective on Inogen from $96.00 to $108.00 and gave the company a “strong-buy” rating in a research note on Friday, June 9th. Finally, J P Morgan Chase & Co increased their price objective on Inogen to $102.00 and gave the company an “overweight” rating in a research note on Monday, June 26th. Three equities research analysts have rated the stock with a hold rating, one has given a buy rating and two have issued a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus target price of $91.60.
Inogen, Inc is a medical technology company. The Company develops, manufactures and markets portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The Company’s Inogen One systems concentrate the air around the patient to offer a single source of supplemental oxygen anytime, anywhere with a portable device.
Receive News & Ratings for Inogen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen Inc and related companies with MarketBeat.com's FREE daily email newsletter.